OncoChek

OncoChek

Oncology An immunoassay intended to detect breast, lung, colon, ovary, prostate, and other CAs, by measuring protein degradation products. See Tumor marker.
References in periodicals archive ?
The enterprise API and genetic variant database developed by Tute is already in use by several European companies including ABL s OncoChek software, DataBiology s Enterprise SaaS tool for oncology, and Patients Know Best s personal health record, said David Ristow, Director of Investment at Eurovestech.
The enterprise API and genetic variant database developed by Tute is already in use by several European companies including ABL's OncoChek software, DataBiology's Enterprise SaaS tool for oncology, and Patients Know Best's personal health record.
The Company's three major proprietary testing products include its DR-70(TM), OncoChek and PyloriProbe(TM) ELISA technologies.
After the pre-clinical trials were initiated, an IVD Technology study noted that OncoChek possesses a competitive advantage over other available products in that it can provide early detection for numerous forms of cancer through significantly increased specificity and sensitivity, thereby making possible the earlier and more effective initiation of treatment for cancer patients.
The Company's proprietary IVD testing products for Cancer Diagnostics include its DR-70 ELISA ('DR-70') technology (for both international and domestic use) for lung cancer detection and its OncoChek ELISA ('OncoChek') technology, currently still under development, for various forms of cancer detection.